BrainEver

Biotechnology · Paris ·

Who is BrainEver

BrainEver is a biopharmaceutical company developing a pipeline of novel therapies for patients with age-related neurodegenerative diseases, such as Charcot disease, Parkinson’s, and glaucoma, the second leading cause of blindness. Our mission is to develop recombinant human Homeoproteins (HPs) to halt disease progression by stopping neuronal loss and durably restoring the physiology and metabolism of the remaining neurons. BrainEver was co-founded by Bernard Gilly (iBionext) and Alain Prochiantz (Collège de France). Our innovative therapeutic approach stems from the pioneering work of Alain Prochiantz and his team on brain development and physiology. Our lead project, BREN02, focuses on developing recombinant human Engrailed-1 (hEN1) for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS). Building on the highly promising results of our preclinical studies, we are preparing to launch clinical trials by 2025. To fund this next phase and secure market approval by 2027, we are opening our capital to those eager to join a unique human and scientific journey. We are supported by prominent investors such as Bpifrance, Ibionext, and Turenne Capital. Now, we aim to raise €35M, with €5M available for participation through the crowdfunding platform Tudigo. Become a BrainEver shareholder 👉 https://tudigo.typeform.com/brainever